Hrt Financial LP Supernus Pharmaceuticals, Inc. Transaction History

Hrt Financial LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$27.57 - $32.91 $968,947 - $1.16 Million	35,145 Added 162.75%	56,739 $1.56 Million
Q2 2023 Aug 11, 2023	SELL	$29.91 - $38.73 $833,591 - $1.08 Million	-27,870 Reduced 56.34%	21,594 $649,000
Q1 2023 May 12, 2023	BUY	$34.93 - $42.03 $635,132 - $764,231	18,183 Added 58.13%	49,464 $1.79 Million
Q4 2022 Feb 10, 2023	SELL	$31.09 - $37.88 $662,745 - $807,487	-21,317 Reduced 40.53%	31,281 $1.12 Million
Q3 2022 Nov 14, 2022	BUY	$28.79 - $35.41 $1.17 Million - $1.44 Million	40,757 Added 344.2%	52,598 $1.78 Million
Q2 2022 Aug 12, 2022	BUY	$25.33 - $34.25 $299,932 - $405,554	11,841 New	11,841 $342,000
Q1 2022 May 16, 2022	SELL	$28.51 - $32.9 $2.3 Million - $2.65 Million	-80,576 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$26.37 - $34.22 $1.56 Million - $2.03 Million	59,202 Added 276.98%	80,576 $2.35 Million
Q3 2021 Nov 15, 2021	BUY	$23.54 - $31.39 $503,143 - $670,929	21,374 New	21,374 $570,000
Q3 2020 Nov 13, 2020	SELL	$20.2 - $25.05 $288,496 - $357,764	-14,282 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$17.09 - $24.89 $244,079 - $355,478	14,282 New	14,282 $339,000

282

60.9M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.94B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.